Home About Login Register Search Archives Announcements

 

Aim and Scope

To provide communication and information exchanging platforms for a broad audience of oncologists, surgeons, medical researchers and professionals working in the field.

Editor-in-Chief

Prof. Dr. Kwong-Kwok Wong
The University of Texas MD Anderson Cancer Center

Indexing and Archiving

Advances in Modern Oncology Research is currently indexed in:

-CAS

  • -CNKI
  • -J-gate
  • -Directory of Open Access Journals (DOAJ)
  • -Google Scholar


AMOR is archived by Portico and the National Library Board of Singapore.

User
Submit Your Manuscript

Downloads

Manuscript Submission Template

ICMJE Conflict of Interest Form

Events

Article Tools
Print this article
Indexing metadata
How to cite item
Finding References
Email this article (Login required)
Email the author (Login required)
Post a Comment (Login required)

Tweets by @AMOR_PiscoMed

Keywords bioinformatics breast cancer breast carcinoma cancer case report chemotherapy cisplatin epidemiology immunotherapy mutation non-small cell lung cancer omics oncology ovarian cancer prostate cancer radiotherapy rectal cancer survival targeted therapy therapy treatment
Home > Vol 3, No 6 (2017) > Sulaiman Shah

Efficacy and safety of pazopanib in advanced renal cell carcinoma treated at University Malaya Medical Centre (UMMC)

Abstract - 1071 PDF - 394
Audi Adawiah Sulaiman Shah, Khairiyah Sidek, Syafirin Ab Sani, Najihah Abu Bakar, Ardif Damiri, Rizma Mohd Zaid, Marniza Saad, Adlinda Alip

Abstract


Background: Pazopanib is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) that was approved as first line treatment for advanced renal cell carcinoma (aRCC). The pivotal trial showed significant increase in median progression free survival (mPFS) of 9.2 months versus 4.0 months with placebo and objective response rate of 30%. Median overall survival (mOS) was 28.4 months with pazopanib. Local data on efficacy and safety of pazopanib is lacking. This study reviewed the efficacy and safety of pazopanib in aRCC in University Malaya Medical Centre (UMMC). Methods: We retrospectively reviewed outcome of patients with advanced renal cell carcinoma who received pazopanib from January 2012 to March 2017. Analysis was done in July 2017. Results: Twenty-one patients were enrolled – 16 (76.2%) were males and five (23.8%) were females. The mean age at diagnosis was 61.9 years old. Majority of the patients were of Chinese ethnicity, (n = 13, 61.9%). Fourteen patients (67%) were diagnosed as metastatic disease at presentation and all had cytoreductive nephrectomy. Eighteen patients (86%) had clear cell histology. The most common metastatic site was lung (66.7%) followed by bone and liver. Except for one, all patients were treated with pazopanib in the first line setting. Majority of the patients (76.2%) was started on pazopanib within a year after diagnosis. Fourteen patients (66%) were started on 800 mg daily as the initial dose. From the analysis, the best tumour response is partial response (n = 8, 38%) followed stable disease (n = 4, 19%). Six patients (28.6%) had progressive disease while three other patients were not assessable. The mPFS was 9 months (95% CI: 7.2 – 10.8) and mOS was 24 months. For toxicity analysis, only 17 patients had side-effects documented in our database. The most common side effects were hypertension (19%) and hand-foot syndrome (19%) followed by diarrheoa (14.3%). Conclusions: In general, pazopanib is well tolerated and demonstrated good PFS and OS in our study population, comparable to previous studies and real-world data. 


Keywords


pazopanib; advanced renal cell carcinoma; treatment

Full Text:

PDF


DOI: http://dx.doi.org/10.18282/amor.v3.i6.282

Refbacks

  • There are currently no refbacks.

Comments on this article

  • Good
    by Mike David (2018-03-10)
  • Sabonete natura todo dia como comprar
    by Liliane Fabres (2018-05-20)
  • A Importância Do Equipamento De Proteção Individual Para Os Profissionais De Saúde Da Central De
    by João das Neves (2018-06-05)
  • Gruporesistencia
    by MariaZaganelli Furtado (2018-06-13)
  • Muito bom
    by YasminMesquita Andrade (2018-06-23)
  • Muito bom
    by EmilyAmorim Belchior (2018-06-27)
  • Muito bom
    by ManuelaGuedes Torres (2018-06-28)
  • Muito bom
    by AmandaBaptista Lancastre (2018-07-01)
  • Free ads posting
    by alvina ash (2018-07-02)
  • Professional Logo Design Service
    by voilet taylor (2018-07-04)
  • paymydoctor.com
    by velevobowi gifto (2018-11-09)
  • Corte e Costura Revelado Como Comprar
    by Alex Rocha (2019-05-09)
  • Cromofina Onde Comprar
    by Alex Rocha (2019-07-19)
  • Concurso INSS Preço
    by Alex Rocha (2019-08-07)
  • Lightmax 30 Anvisa
    by Alex Rocha (2019-08-07)
  • Alivi Pros Anvisa
    by Alex Rocha (2019-08-20)
View all comments


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Bookmark and Share
                                       

© 2017 by PiscoMed Publishing Pte Ltd